2016 annual financial data
CRISPR Therapeutics 2016 Operating margin
Direct answer
Operating margin was -1,319.33%.
Operating income was -68,130,000 USD and net income was -23,202,000 USD.
Operating cash flow was -55,310,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 5,164,000 USD
- Operating income
- -68,130,000 USD
- Net income
- -23,202,000 USD
- Operating cash flow
- -55,310,000 USD